S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
South Korean doctors hold massive anti-government rally over medical school recruitment plan
Critical asset just had biggest fall on record (Ad)
Nobel laureate Muhammad Yunus is granted bail in a Bangladesh graft case
The former chairman of the state-owned Bank of Beijing is being investigated for alleged corruption
Critical asset just had biggest fall on record (Ad)
Trader Joe's chicken soup dumplings recalled for possibly containing permanent marker plastic
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
Critical asset just had biggest fall on record (Ad)
What to watch for as China's major political meeting of the year gets underway
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
South Korean doctors hold massive anti-government rally over medical school recruitment plan
Critical asset just had biggest fall on record (Ad)
Nobel laureate Muhammad Yunus is granted bail in a Bangladesh graft case
The former chairman of the state-owned Bank of Beijing is being investigated for alleged corruption
Critical asset just had biggest fall on record (Ad)
Trader Joe's chicken soup dumplings recalled for possibly containing permanent marker plastic
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
Critical asset just had biggest fall on record (Ad)
What to watch for as China's major political meeting of the year gets underway
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
South Korean doctors hold massive anti-government rally over medical school recruitment plan
Critical asset just had biggest fall on record (Ad)
Nobel laureate Muhammad Yunus is granted bail in a Bangladesh graft case
The former chairman of the state-owned Bank of Beijing is being investigated for alleged corruption
Critical asset just had biggest fall on record (Ad)
Trader Joe's chicken soup dumplings recalled for possibly containing permanent marker plastic
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
Critical asset just had biggest fall on record (Ad)
What to watch for as China's major political meeting of the year gets underway
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
South Korean doctors hold massive anti-government rally over medical school recruitment plan
Critical asset just had biggest fall on record (Ad)
Nobel laureate Muhammad Yunus is granted bail in a Bangladesh graft case
The former chairman of the state-owned Bank of Beijing is being investigated for alleged corruption
Critical asset just had biggest fall on record (Ad)
Trader Joe's chicken soup dumplings recalled for possibly containing permanent marker plastic
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
Critical asset just had biggest fall on record (Ad)
What to watch for as China's major political meeting of the year gets underway
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet
NASDAQ:RNA

Avidity Biosciences (RNA) Stock Price, News & Analysis

$20.11
+1.81 (+9.89%)
(As of 03/1/2024 ET)
Today's Range
$18.38
$20.35
50-Day Range
$9.05
$20.11
52-Week Range
$4.82
$24.84
Volume
2.43 million shs
Average Volume
896,545 shs
Market Capitalization
$1.61 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$31.60

Avidity Biosciences MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
57.1% Upside
$31.60 Price Target
Short Interest
Bearish
9.68% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.28mentions of Avidity Biosciences in the last 14 days
Based on 26 Articles This Week
Insider Trading
Selling Shares
$128,610 Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($3.50) to ($3.51) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.05 out of 5 stars

Medical Sector

817th out of 947 stocks

Pharmaceutical Preparations Industry

374th out of 437 stocks


RNA stock logo

About Avidity Biosciences Stock (NASDAQ:RNA)

Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease is under phase 1/2 clinical trial. Its other products in pipeline include AOC 1044 for the treatment of Duchenne Muscular Dystrophy, which is under phase 1/2 clinical trial; and AOC 1020 to treat facioscapulohumeral muscular dystrophy is in phase 1/2 clinical trial. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.

RNA Stock Price History

RNA Stock News Headlines

Avidity Biosciences (NASDAQ:RNA) Shares Up 9.2%
Critical asset just had biggest fall on record
What many consider America's critical financial asset suffers biggest fall on record. Expert says: "it's very bad for millions, protect yourself now."
Avidity Biosciences Inc
Critical asset just had biggest fall on record
What many consider America's critical financial asset suffers biggest fall on record. Expert says: "it's very bad for millions, protect yourself now."
Avidity Biosciences Honors Rare Disease Day®
TD Cowen Reaffirms Their Buy Rating on Avidity Biosciences (RNA)
3 Highly Rated Biotech Stocks to Buy for 300% Gains
RNA Mar 2024 22.500 call
RNA Sep 2024 22.500 call
Avidity Biosciences' AOC 1044 Gets FDA Rare Pediatric Disease Designation
RNA Mar 2024 25.000 call
See More Headlines
Receive RNA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Avidity Biosciences and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/09/2021
Today
3/03/2024
Next Earnings (Estimated)
5/14/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:RNA
Fax
N/A
Employees
186
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$31.60
High Stock Price Target
$50.00
Low Stock Price Target
$20.00
Potential Upside/Downside
+57.1%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
5 Analysts

Profitability

Net Income
$-173,990,000.00
Net Margins
-2,219.87%
Pretax Margin
-2,219.87%

Debt

Sales & Book Value

Annual Sales
$9.56 million
Book Value
$6.27 per share

Miscellaneous

Free Float
78,243,000
Market Cap
$1.61 billion
Optionable
Optionable
Beta
0.71
10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Key Executives

  • Dr. Troy Edward Wilson J.D. (Age 55)
    Ph.D., Co-Founder & Chairman
    Comp: $67.5k
  • Ms. Sarah Boyce (Age 52)
    President, CEO & Director
    Comp: $1.05M
  • Mr. Michael F. MacLean (Age 58)
    Chief Financial & Chief Business Officer
    Comp: $701.64k
  • Dr. W. Michael Flanagan Ph.D. (Age 62)
    Chief Scientific & Technical Officer
    Comp: $678.74k
  • Ms. Teresa McCarthy (Age 60)
    Chief Human Resources Officer
    Comp: $665.14k
  • Mr. Eric B. Mosbrooker (Age 56)
    Chief Strategy Officer
    Comp: $42.5k
  • Prof. Mark E. Davis
    Scientific Founder, Member of Scientific Advisory Board and Member of Board of Managers
  • Dr. Frank P. McCormick Ph.D. (Age 74)
    Scientific Founder & Member of Scientific Advisory Board
  • Mr. Geoffrey M. Grande C.F.A.
    VP of Investor Relation & Corporate Communication
  • Dr. John W. Wallen III (Age 66)
    VP of Intellectual Property, General Counsel & Secretary














RNA Stock Analysis - Frequently Asked Questions

Should I buy or sell Avidity Biosciences stock right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Avidity Biosciences in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" RNA shares.
View RNA analyst ratings
or view top-rated stocks.

What is Avidity Biosciences' stock price target for 2024?

5 brokerages have issued 1 year price targets for Avidity Biosciences' stock. Their RNA share price targets range from $20.00 to $50.00. On average, they predict the company's share price to reach $31.60 in the next twelve months. This suggests a possible upside of 57.1% from the stock's current price.
View analysts price targets for RNA
or view top-rated stocks among Wall Street analysts.

How have RNA shares performed in 2024?

Avidity Biosciences' stock was trading at $9.05 at the beginning of the year. Since then, RNA shares have increased by 122.2% and is now trading at $20.11.
View the best growth stocks for 2024 here
.

When is Avidity Biosciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024.
View our RNA earnings forecast
.

How were Avidity Biosciences' earnings last quarter?

Avidity Biosciences, Inc. (NASDAQ:RNA) issued its earnings results on Tuesday, November, 9th. The biotechnology company reported ($0.68) earnings per share for the quarter, hitting the consensus estimate of ($0.68). The biotechnology company earned $2.16 million during the quarter, compared to the consensus estimate of $1.50 million. Avidity Biosciences had a negative net margin of 2,219.87% and a negative trailing twelve-month return on equity of 39.74%.

What ETFs hold Avidity Biosciences' stock?

ETFs with the largest weight of Avidity Biosciences (NASDAQ:RNA) stock in their portfolio include Morningstar US Small Growth (MSGR) and Direxion Moonshot Innovators ETF (MOON).Simplify Propel Opportunities ETF (SURI).

What other stocks do shareholders of Avidity Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Avidity Biosciences investors own include GTX (GTXI), Inovio Pharmaceuticals (INO), Novavax (NVAX), Sarepta Therapeutics (SRPT), Avid Bioservices (CDMO), Dynavax Technologies (DVAX), iBio (IBIO), Intel (INTC), Ariad Pharmaceuticals (ARIA) and Corcept Therapeutics (CORT).

When did Avidity Biosciences IPO?

(RNA) raised $150 million in an initial public offering (IPO) on Friday, June 12th 2020. The company issued 10,000,000 shares at $14.00-$16.00 per share. Cowen, SVB Leerink, Credit Suisse and Wells Fargo Securities acted as the underwriters for the IPO.

Who are Avidity Biosciences' major shareholders?

Avidity Biosciences' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Price T Rowe Associates Inc. MD (9.33%), Price T Rowe Associates Inc. MD (9.33%), Vanguard Group Inc. (5.46%), Artisan Partners Limited Partnership (2.84%), Dimensional Fund Advisors LP (2.02%) and Balyasny Asset Management L.P. (1.64%). Insiders that own company stock include Arthur A Levin, Michael F Maclean, Rtw Investments, Lp, Sarah Boyce and W Michael Flanagan.
View institutional ownership trends
.

How do I buy shares of Avidity Biosciences?

Shares of RNA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:RNA) was last updated on 3/3/2024 by MarketBeat.com Staff